Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. The company is headquartered in Watertown, Massachusetts and currently employs 131 full-time employees. The company went IPO on 2013-03-21. The firm is engaged in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. The Company’s clinical programs are focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including receptor tyrosine kinase (KIT) and STAT6 inhibition. The firm has two clinical-stage product candidates for RSV, which are zelicapavir and EDP-323. Glecaprevir, a protease inhibitor discovered by the Company, is part of one of the treatment regimens for curing chronic hepatitis C virus (HCV) infection and is sold by AbbVie in various countries under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). The firm also has development programs in virology for SARS-CoV-2 and Hepatitis B virus.
Follow-Up Questions
Who is the CEO of Enanta Pharmaceuticals Inc?
Dr. Jay Luly is the President of Enanta Pharmaceuticals Inc, joining the firm since 2003.
What is the price performance of ENTA stock?
The current price of ENTA is $7.75, it has decreased 1.08% in the last trading day.
What are the primary business themes or industries for Enanta Pharmaceuticals Inc?
Enanta Pharmaceuticals Inc belongs to Biotechnology industry and the sector is Health Care
What is Enanta Pharmaceuticals Inc market cap?
Enanta Pharmaceuticals Inc's current market cap is $165.8M
Is Enanta Pharmaceuticals Inc a buy, sell, or hold?
According to wall street analysts, 9 analysts have made analyst ratings for Enanta Pharmaceuticals Inc, including 3 strong buy, 6 buy, 3 hold, 0 sell, and 3 strong sell
